TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients

Infectious Agents and Cancer

Volumn 6, Issue 1, 2011, Pages

  Di Vuolo, Valeria ^a   Buonaguro, Luigi ^a   Izzo, Francesco ^a   Losito, Simona ^a   Botti, Gerardo ^a   Buonaguro, Franco M ^a   Tornesello, Maria Lina ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Genetic Polymorphisms; hepatocellular carcinoma; MDM2 SNP309; TP53 codon 72

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS CARCINOGENESIS; VIRUS HEPATITIS;

EID: 80051592011     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-6-13     Document Type: Article

References (45)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010
2. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis 2. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, et al. Int J Cancer 2011 128 176 184 10.1002/ijc.25321 20232388
3. Changing incidence of hepatocellular carcinoma in Japan. Okuda K, Fujimoto I, Hanai A, Urano Y, Cancer Res 1987 47 4967 4972 3040235 (Pubitemid 17143048)
4. Trends in primary liver cancer. Deuffic S, Poynard T, Buffat L, Valleron AJ, Lancet 1998 351 214 215 9449893
5. Increase in primary liver cancer in the UK, 1979-94. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC, Lancet 1997 350 1142 1143 9343506 (Pubitemid 27454010)
6. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA, Ann Intern Med 2003 139 817 823 14623619
7. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection 1. Chuang SC, La VC, Boffetta P, Cancer Lett 2009 286 9 14 10.1016/j.canlet.2008.10.040 19091458
8. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence 1. Donato F, Gelatti U, Limina RM, Fattovich G, Oncogene 2006 25 3756 3770 10.1038/sj.onc.1209557 16799617 (Pubitemid 43980471)
9. A case-control study of hepatocellular carcinoma in Osaka, Japan. Tsukuma H, Hiyama T, Oshima A, Sobue T, Fujimoto I, Kasugai H, et al. Int J Cancer 1990 45 231 236 10.1002/ijc.2910450205 2154409 (Pubitemid 20061374)
10. The natural history of hepatocellular carcinoma. Romeo R, Colombo M, Toxicology 2002 181-182 39 42 12505282 (Pubitemid 36015670)
11. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, et al. Eur J Cancer 2008 44 847 853 10.1016/j.ejca.2008.01.025 18313290
12. Primary structure polymorphism at amino acid residue 72 of human p53. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV, Mol Cell Biol 1987 7 961 963 3547088 (Pubitemid 17004567)
13. Polymorphisms in the p53 pathway. Pietsch EC, Humbey O, Murphy ME, Oncogene 2006 25 1602 1611 10.1038/sj.onc.1209367 16550160
14. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. Cell 2004 119 591 602 10.1016/j.cell.2004.11.022 15550242 (Pubitemid 39535748)
15. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. J Med Genet 2006 43 531 533 10.1136/jmg.2005.037952 16258005 (Pubitemid 43927330)
16. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, et al. Eur J Hum Genet 2007 15 110 114 10.1038/sj.ejhg.5201715 17003841 (Pubitemid 44921674)
17. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. Cancer Res 2006 66 5104 5110 10.1158/0008-5472.CAN-06-0180 16707433 (Pubitemid 43844932)
18. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection 1. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. Carcinogenesis 2008 29 1192 1196 10.1093/carcin/bgn090 18390844 (Pubitemid 351964880)
19. Evaluating the role of human papillomaviruses in conjunctival neoplasia. Tornesello ML, Duraturo ML, Waddell KM, Biryahwaho B, Downing R, Balinandi S, et al. Br J Cancer 2006 94 446 449 10.1038/sj.bjc.6602921 16404433 (Pubitemid 43237568)
20. TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, et al. Oncology 2009 77 328 334 10.1159/000260905 19940524
21. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Tornesello ML, Buonaguro L, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, et al. Biomarkers 2011 16 42 50 10.3109/1354750X.2010.525664 20979563
22. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. Hrstka R, Coates PJ, Vojtesek B, J Cell Mol Med 2009 13 440 453 10.1111/j.1582-4934.2008.00634.x 19379143
23. p53 polymorphisms: cancer implications. Whibley C, Pharoah PD, Hollstein M, Nat Rev Cancer 2009 9 95 107 10.1038/nrc2584 19165225
24. Immunohistochemical localization of cdc6 in squamous and glandular neoplasia of the uterine cervix. Bonds L, Baker P, Gup C, Shroyer KR, Arch Pathol Lab Med 2002 126 1164 1168 12296751
25. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. J Natl Cancer Inst 2006 98 285 288 10.1093/jnci/djj054 16478747 (Pubitemid 43264712)
26. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. Capasso M, Ayala F, Avvisati RA, Russo R, Gambale A, Mozzillo N, et al. J Hum Genet 2010
27. P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Bonafe M, Olivieri F, Mari D, Baggio G, Mattace R, Berardelli M, et al. Am J Hum Genet 1999 65 1782 1785 10.1086/302664 10577935 (Pubitemid 30468693)
28. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Cancer Lett 2004 208 75 79 10.1016/j.canlet.2004.02.016 15105048 (Pubitemid 38501786)
29. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM, Cancer Lett 2003 193 199 205 10.1016/S0304-3835(03)00046-6 12706878 (Pubitemid 36428903)
30. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El KL, Afifi R, et al. Hepatol Res 2007 37 748 754 10.1111/j.1872-034X.2007.00126.x 17573955 (Pubitemid 47054781)
31. p53 codon 72 polymorphism and liver cancer susceptibility: A meta-analysis of epidemiologic studies. Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF, World J Gastroenterol 2011 17 1211 1218 10.3748/wjg.v17.i9.1211 21448428
32. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ, Hepatology 1999 29 697 702 10.1002/hep.510290330 10051470
33. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. Clin Cancer Res 2006 12 4867 4871 10.1158/1078-0432.CCR-06-0111 16914573 (Pubitemid 44338572)
34. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ, World J Gastroenterol 2009 15 5592 5597 10.3748/wjg.15.5592 19938200
35. MDM2 SNP309T > G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Ezzikouri S, El Feydi AE, Afifi R, El KL, Benazzouz M, Hassar M, et al. Cancer Detect Prev 2009 32 380 385 10.1016/j.cdp.2009.01.003 19233569
36. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Akkiz H, Sumbul AT, Bayram S, Bekar A, Akgollu E, Cancer Epidemiol 2010 34 448 452 10.1016/j.canep.2010.04.008 20447891
37. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ, J Cancer Res Clin Oncol 2011
38. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells 1. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, et al. J Biol Chem 2005 280 26776 26787 10.1074/jbc.M505203200 15908423 (Pubitemid 41040711)
39. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Bond GL, Hu W, Levine A, Cancer Res 2005 65 5481 5484 10.1158/0008-5472.CAN-05-0825 15994915 (Pubitemid 40911143)
40. The p53-Mdm2 module and the ubiquitin system. Michael D, Oren M, Semin Cancer Biol 2003 13 49 58 10.1016/S1044-579X(02)00099-8 12507556 (Pubitemid 36269180)
41. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, et al. Clin Cancer Res 2007 13 4123 4129 10.1158/1078-0432.CCR-07-0609 17634539 (Pubitemid 47108171)
42. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME, Mol Cell Biol 2003 23 462 472 10.1128/MCB.23.2.462-473.2003 12509446 (Pubitemid 36050541)
43. HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding. Gong GZ, Jiang YF, He Y, Lai LY, Zhu YH, Su XS, World J Gastroenterol 2004 10 2223 2227 15259070 (Pubitemid 39144972)
44. HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines. Siavoshian S, Abraham JD, Kieny MP, Schuster C, Arch Virol 2004 149 323 336 10.1007/s00705-003-0205-7 14745598 (Pubitemid 38192681)
45. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, et al. Oncogene 2002 21 4801 4811 10.1038/sj.onc.1205589 12101418 (Pubitemid 34879455)